Zachary Rome - PaxMedica, Common COO Director
| PXMDDelisted Stock | USD 0.86 0.18 17.31% |
Insider
Zachary Rome is COO Director of PaxMedica, Common Stock
| Age | 40 |
| Phone | 914 987 2876 |
| Web | https://www.paxmedica.com |
Zachary Rome Latest Insider Activity
Tracking and analyzing the buying and selling activities of Zachary Rome against PaxMedica, Common pink sheet is an integral part of due diligence when investing in PaxMedica, Common. Zachary Rome insider activity provides valuable insight into whether PaxMedica, Common is net buyers or sellers over its current business cycle. Note, PaxMedica, Common insiders must abide by specific rules, including filing SEC forms every time they buy or sell PaxMedica, Common'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Zachary Rome over a year ago Sale by Zachary Rome of 20000 shares of PaxMedica Common |
PaxMedica, Common Management Efficiency
The company has return on total asset (ROA) of (2.5596) % which means that it has lost $2.5596 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.4696) %, meaning that it created substantial loss on money invested by shareholders. PaxMedica, Common's management efficiency ratios could be used to measure how well PaxMedica, Common manages its routine affairs as well as how well it operates its assets and liabilities.PaxMedica, Common Stock currently holds 173.54 K in liabilities with Debt to Equity (D/E) ratio of 0.07, which may suggest the company is not taking enough advantage from borrowing. Debt can assist PaxMedica, Common until it has trouble settling it off, either with new capital or with free cash flow. So, PaxMedica, Common's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like PaxMedica, Common Stock sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for PaxMedica, to invest in growth at high rates of return. When we think about PaxMedica, Common's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Cameron Shaw | Virax Biolabs Group | 37 | |
| Gordon JD | Quoin Pharmaceuticals Ltd | 60 | |
| Pablo MD | ZyVersa Therapeutics | N/A | |
| Brian Strem | Kiora Pharmaceuticals | 44 | |
| Sharon McBrayer | Palisade Bio | N/A | |
| MD MBA | Kiora Pharmaceuticals | 50 | |
| MaryJane Rafii | Kiora Pharmaceuticals | N/A | |
| DSc MSE | Immix Biopharma | 75 | |
| Carol Odle | Revelation Biosciences | N/A | |
| MBA JD | Cardio Diagnostics Holdings | 60 | |
| Melissa Tosca | Kiora Pharmaceuticals | N/A | |
| John CPA | Unicycive Therapeutics | 62 | |
| Meeshanthini Dogan | Cardio Diagnostics Holdings | 35 | |
| MBA MD | Immix Biopharma | 49 | |
| Steen Knudsen | Allarity Therapeutics | 63 | |
| Jason Davis | Virax Biolabs Group | 52 | |
| Annie Rasmussen | Allarity Therapeutics | 67 | |
| Karen Cashmere | ZyVersa Therapeutics | 72 | |
| Robert McRae | Palisade Bio | N/A | |
| MPA MD | Unicycive Therapeutics | 51 | |
| Joan Brown | Allarity Therapeutics | 70 | |
Management Performance
| Return On Equity | -10.47 | ||||
| Return On Asset | -2.56 |
PaxMedica, Common Stock Leadership Team
Elected by the shareholders, the PaxMedica, Common's board of directors comprises two types of representatives: PaxMedica, Common inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PaxMedica,. The board's role is to monitor PaxMedica, Common's management team and ensure that shareholders' interests are well served. PaxMedica, Common's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PaxMedica, Common's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Howard Weisman, CEO Director | ||
| MS MBA, Ex Chairman | ||
| Zachary Rome, COO Director | ||
| Stephen Sheldon, Chief Officer | ||
| David MD, Chief Officer |
PaxMedica, Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is PaxMedica, Common a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -10.47 | ||||
| Return On Asset | -2.56 | ||||
| Current Valuation | 388.33 K | ||||
| Shares Outstanding | 7.47 M | ||||
| Shares Owned By Insiders | 8.14 % | ||||
| Shares Owned By Institutions | 1.60 % | ||||
| Number Of Shares Shorted | 637.72 K | ||||
| Price To Earning | 1.90 X | ||||
| Price To Book | 1.83 X | ||||
| EBITDA | (16.15 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Consideration for investing in PaxMedica, Pink Sheet
If you are still planning to invest in PaxMedica, Common Stock check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PaxMedica, Common's history and understand the potential risks before investing.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |